Insourcing Model Improves Operational Efficiency
Mar 18 2017 Comments 0
French Contract Research Organisation (CRO) NovAliX is to deliver on-site discovery chemistry services to support small molecules drug discovery programs under a multi-year insourcing agreement with Belgian biopharmaceutical company UCB Biopharma.
NovAliX offers a collaborative model for insourcing operations in chemistry, biophysics and drug discovery. Its model is based on the proximity created by the client’s and NovAliX’s teams both operating on the client’s site. This proximity allows faster turnaround time and improves cost efficiency, thanks to the optimal use of existing available research laboratories and equipment at the client’s premises. This insourcing model also enables local teams at various sites to share best practices to improve efficiency.
“This new collaborative agreement acknowledges not only the benefits of insourcing as a cost-efficient sourcing approach, it also proves that it’s a scientifically sound model,” said Stephan Jenn, president of NovAliX. “Our agreement with UCB shows that pharma companies today focus on new innovative sourcing models.”
NovAliX currently works with five partners from the top 50 pharma companies as well as seven research sites across Europe, all operating on the co-located research program model.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
Jan 24 2018 Cardiff, UK
Dec 11 2017 Berlin, Germany
Nov 29 2017 Antwerp, Belgium
Nov 21 2017 Manchester. UK
Nov 16 2017 Izmir, Turkey